Shvoong Home>Medicine & Health>The Experimental Study on a New Anti-bone Loss Agent RGD-Peptide (225) Review

The Experimental Study on a New Anti-bone Loss Agent RGD-Peptide (225)

Article Review

   by:TsingHua    
Original Author: Chinese General Practice
Objective This study is to observe the effects of RGD- peptide (225) (RGD) with 17β-Estrodiol (E 2) on bone mass,bone mechanical strength and bone metabolism in ovariectomized (OVX) mice.Methods Bone mineral density (BMD),Bone mineral contend (BMC),bone strength and biochemical markers were measured in each group.45(10-week-old) female CD-1 mice,with an average weight of 29 g,were randomly divided into 5 groups.17β-Estradiol (15μg·kg -1·d -1,injection),RGD-peptide (225) (35 nmol/mouse·d) injection for 7 weeks in ovariectomized mice.And it was compared with sham group and BL group.Results Biomechanical parameters decreased,BMD and BMC decreased obviously,and bone turnover also accelerated in OVX mice,compared with sham operated group.After 7 weeks' treatment,the BMD and BMC of RGD Pdypeptide (225) were obviously increased.A part of biomechanical parameters increased and serum ALP significantly decreased in RGD and E 2 group.Conclusion RGD-peptide (225) may increase BMD,BMC,and improve the bone mechanical strength and inhibit the bone turnover obviously.
Published: February 05, 2005
Please Rate this Review : 1 2 3 4 5

.

  • Sign up
  • ‎What is Shvoong?‎
  • Sign In
    Sign In
    Remember my username Forgot your password?
  • Write & earn

Summaries and Short Reviews

.